Дополнение к главе 4

We use cookies. Read the Privacy and Cookie Policy

Дополнение к главе 4

1. Jakes, Rupert W, Duffy, Stephen W, Ng, Fook-Cheong, Gao, Fei, Ng, Eng-Hen, Scow, Adeline, Lee, Hin-Peng and Yu, Mimi C., 2002. Mammographic Parenchymal Patterns and Self-re-ported Soy Intake in Singapore Chinese Women. Cancer Epidemiology Biomarkers & Prevention, 11, 608–613.

2. Pringle, H., 1998. Neolithic agriculture: reading the signs of ancient animal domestication. Science. 282, 1448.

3. Thomas M and others, 2007, Proc Nat Acad Sei.

4. Latham, M.C., 1997. Human nutrition in the developing world, Rome, 1997. FAO Food and Nutrition Series № 29, Cornell University, Ithaca, NY.

5. Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

6. AbuGhazaleh, A.A. and others, 2004. CLA increases in milk when cows fed fish meal and extruded soybeans for an extended period of tim t. Journal of Dairy Science, 87 (6), 1758–1766.

7. Petit, H.V., 2002. Digestion, milk production, milk composition, and blood composition of dairy cows fed whole flax seed. Journal of Dairy Science, 85 (6), 1482–1490.

8. Wahle, K.W and others, 2004. CLAs: are they beneficial or detrimental to health? Progress in Lipid Research, 43 (6), 553–587.

9. Willett, WC, and Stampfer, M.J., 2007. Rebuilding the food pyramid. Scientific American, Special edition on diet and health, February 2007, 12–21.

10. The Royal Society, 2000. Endocrine-disrupting chemicals. Document 06/00. The Royal Society.

11. Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

12. Qin, L.Q. and others, 2004. Estrogen: one of the risk factors in milk for prostate cancer. Medical Hypotheses, 62 (1), 133–142.

13. Hartman, S. and others, 1998. Natural occurrence of steroid hormones in food. Food Chemistry, 62, 7-20.

14. Buder, J., 2006. White lies. Vegetarian and Vegan Foundation.

15. Ganmaa, D. and Sato, A., 2005. Possible role of female sex hormones in milk from pregnant cows in the development of breast, ovarian and corpus uteri cancers. Medical Hypotheses, 65 (6), 1028–1037.

16. DEFRA, 2005. Agriculture in the UK, 2004. Norwich, UK: HMSO.

17. Campbell, T.C. and Junshi, C., 1994. Diet and chronic degen erative disease perspectives from China. Am J Clin Nutr, 59, Suppl., 11 535-11 615.

18. Charatan, Fred, 2003. Book Review: Fat Land: How Americans Became the Fattest People in the World, by Greg Critser. BMJ, 326, 229.

19. Charatan, Fred, 2003. Book Review: Fat Land: How Americans Became the Fattest People in the World, by Greg Critser. BMJ, 326, 229.

20. Charatan, Fred, 2003. Book Review; Fat Land; How Americans Became the Fattest People in the World, by Greg Critser. BMJ, 326, 229.

21. Grosvenor, C.E. and others, 1992. Hormones and growth factors in milk. Endocrine Reviews, 14 (6), 710–728.

22. http://www.dhn.csiro.au/crctissue.html

23. http://www.13.waisays.com/cancer2.htm

24. le Huerou-Luron, I. and others, 1998. Source of dietary protein influences kinetics of plasma gut regulatory peptide concentration to feeding in preruminant calves. Comparative Biochemistry and Physiology: A – Molecular and Integrative Physiology, 119 (3), 817–824.

25. Koldovski, O. and others, 1995. Milk-borne hormones: possible tools of communication between mother and suckling. Physiological Research, 1995, 44 (6), 349–351, Koldovsky, O. and others, 1994. Hormonally active peptides in human milk. Acta Paediatrica Suppl., 402, 89–93; Lehy,T. and others, 1990. Promoting effect of bombesin on the cell proliferation in the rat endocrine pancreas during the early post natal period. Regulatory Peptides, 27 (1), 87–96; Pollack, P.F., 1989. Effects of enterally– and parenterally-administrated bombesin on intestinal luminal tryptic activity and protein in the suckling rat. Ex-perienta, 45 (4), 385–388; Lazarus, L.H. and others, 1986. An immunoreactive peptide in milk contains bombesin-like bioactivity. Experienta, 42 (7), 822–823; Jahnke, G.D. and others, 1984. A bombesin immunoreactive peptide in milk. Proc Natl Acad Sei USA, 81 (2), 578–582.

26. Berseth, C.I. and others, 1990. Postpartum changes in pattern of gastrointestinal regulatory peptides in human milk. Am J ClinNutr, 51 (6), 985–990.

27. Burns, D.M. and others, 1999. Breast cancer cell-associated en-dopeptidase EC24.11 modulates proliferative response to bombesin, British Journal of Cancer, 79 (2), 214–220; Bold, R.J, and others, 1998. Bombesin stimulates in vitro growth of human breast cancer independent of estrogen receptor status. Anticancer Research, 18 (16A), 4051–4056; Miyazaki, M. and others, 1998. Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-11 and RC-3095. European Journal of Cancer, 34 (5), 710–717; Nelson, J, and others,

1991. Bombesin stimulates proliferation of human breast cancer cells in culture. Br. J. Cancer, 63 (6), 933–936; Giacchetti, S. and others, 1990. Characterization, in some human breast can-

cer cell lines, of gastrin-releasing peptide-like receptors which are absent in normal breast epithelial cells. Int J Cancer, 46 (2), 293–298; Weber, C.J. and others, 1989. Gastrin-releasing peptide, calcitonin gene-related peptide, and calcitonin-like immu-no-reactivity in human breast cyst fluid and gastrin-releasing peptide-like immunoreactivity in human breast carcinoma cell lines. Surgery, (6), 1134–1139 (disc. 1139–1140).

28. Markwalder, R. and others, 1999. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Research, 59 (5), 1152–1159; Festuccia, C. and others, 1998. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Int. J. Cancer, 75 (3); 418–431: Krongrad, A. and others, 1997. Endopeptidase 24.11 activity in the human prostate cancer cell lines LNCaP and PPC-1. Urological Research, 25 (2), 113–116; Jungwirth, A. and others, 1997. LHRH antagonist Cetrolix (SB-75) and bombesin-antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate, 32 (3), 164–172; Larran, J. and others, 1996. In vitro characterization of bombesin and calcitonin on the proliferation of PC3, DK145 and LNCaP cancer prostatic cell lines. International Journal of Developmental Biology, 1996 (Suppl. 1), 275S-276S; Aprickian, A.G. and others, 1996. Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostatic cancer cells. Journal of Molecular Endocrinology, 16 (3), 297–306; Bologna, M. and others, 1989. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer, 63 (9), 1714–1720; Wasilenko, WJ. and others, 1996. Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines. Int J Cancer, 68 (2), 259–264.

29. Takeyama, M. and others, 1989. Enzyme immunoassae of gastrin-releasing, peptide (GRP)-like immunoreactivity in milk. Int J Pept Protein Res, 34 (1), 70–74.

30. Ducroc, R. and others, 1995. Immunoreactive substance P and calcitonin-gene-related peptide (CGRP) in rat milk and in human milk and infant formula’s. Am J Clin Nutr, 62 (3), 554–558.

31. Lembeck, F. and others, 1979. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Arch Pharmacol, 310 (2), 175–183.

32. Khare, V K. and others, 1998. The neuropeptide/mast cell secretagogue substance F is expressed in cutaneous melano-cyticlesions. Journal of Cutaneous Pathology, 25 (1), 2-10.

33. Ducroc, R. and others, 1995. Immunoreactive substance P and calcitonin-gene-related peptide (CGRP) in rat milk and in human milk and infant formula’s. Am J Clin Nutr, 62 (3), 554–558.

34. Faulkner, A., 1998. Insulin-like growth factor 1 concentrations in milk and plasma after growth hormone treatment. Biochemical Society Transactions, 26 (4), 386; Silanikove, N. and others, 1998. Metabolic and productive response of dairy cows to increased ion supplementation at early lactation in warm weather. Journal of Dairy Research, 65 (4), 529–543; Ginjala, V. and others, 1998. Determination of transforming growth factor-beta 1 (TGF-beta 1) and insulin-like growth factor-1 (IGF-1) in bovine colostreum samples. Journal of Immunoassay, 19 (2–3), 195–207; Schober, D.A. and others, 1990. Perinatal expression of type 1 IGF receptors in porcine small intestine. Endocrinology, 126 (2), 1125–1132.

35. Rao, R.K. and others, 1998. Luminal stability of insulin-like growth factor-1 and -2 in developing rat gastrointestinal tract. Journal of Pediatric Gastroenterology and Nutrition, 26 (2), 179–185.

36. Parisot, J.P. and others, 1999. Altered expression of the insulinlike growth factor-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br J Cancer, 79 (5–6), 693–700; Sciacca, L. and others, 1999. Insulin receptor activation by insulin-like growth factor-2 in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene, 18 (15), 2471–2479; Grothey, A. and others, 1999. The role of insuline-like growth factor and its receptor in cell growth transformation, apopto-sis, and chemoresistance In solid tumor s. Journal of Cancer Research and Clinical Oncology, 125 (3–4), 166–173; Perks, C. M. and others, 1999. Activation of integrin and ceramide signalling pathways can inhibit the mitogenic effect of insulin-like growth factor-1 (IGF-1) in human breast cancer cell lines. Br J Cancer, 79 (5–6), 701–706; de Cupis, A. and others, 1998. Responsiveness to hormone, growth factor and drug treatment of a human breast cancer cell line; comparison between early and late cultures. In Vitro Cellular and Developmental Biology – Animal, 34 (10), 836–843; Kobari, M. and others, 1998. The inhibitory effect of an epidermal growth factor receptor specific tyrokinase inhibitor on pancreatic cancer cell lines was more potent than inhibitory antibodies against the receptors for EGF and IGF-1. International Journal of Pancreatology, 24

(2), 85–95; Gooch, J.L. and others, 1998. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res, 58 (18), 4199–4205; Choki, I. and others, 1998. Osteobiast-derived growth factors enhance adriamycin-cytos-tasis of MCF-7 human breast cancer cells. AnticancerRes, 18 (16A), 4213–4224; Jackson, J.G. and others, 1998, Insulin receptor substrate-1 is the predominant signalling molecule activated by insulin-like growth factor-1, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. Journal of Biological Chemistry, 273 (16), 9994-10 003; Westley,

B.R. and others, 1998. Interactions between the oestrogen and IGF signalling pathways in the control of breast epithelial cell proliferation. Biochemical Society Symposium, 63, 35–44; Sur-macz, E. and others, 1995. Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. Clinical Cancer Research, 1 (11), 1429–1436.

37. Untersasser, G. and others, 1999. Proliferative disorders of the aging human prostate: involvement of protein hormones and their receptors. Experimental Gerontology, 34 (2), 275–287; Xu, Z.D., 1999. Hammerhead ribozyme-mediated cleavage of the human insulin-like growth factor-2 ribonucleic acid in vitro and in prostate cancer cells. Endocrinology, 140 (5), 2134–2144; Marelli, M.M. and others, 1999. Luteinizing hormone-releasing hormone agonists interfere with the antagonic activity of the insulin-like growth factor system in androgen-dependent prostate cancer cells. Endocrinology, 140 (1), 329–334; Larnharzi, N. and others, 1998. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DY-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor-2 in tumors. Proc Natl Acad Sei USA, 95 (15), 8864–8868; Wang, Y.Z. and others, 1998. Sex hormone-induced prostatic carcinogenesis in the noble rat; the role of insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) in the development of cancer. Prostate, 35 (3), 165–177.

38. He, Y., 1999. Comment on the Association between Insulin-Like Growth Factor-1 (IGF-I) and Bone Mineral Density: Further Evidence Linking IGF-I to Breast Cancer Risk. Journal of Cellular Endocrinology and Metabolism, 84, 1760.

39. Perks, C. M. and Holly, J.M.P., 2000, Insulin-Like Growth Factor Binding Proteins (IGFBPs) in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 5, 75–84.

40. Murphy, M.S. and others, 1998. Growth factors and the gastrointestinal tract. Nutrition, 14 (10), 771–774; Buts, J.F., 1998, Bioactive factors in milk, (in French.) Archives de Pediatrie, 5 (3), 298–306.

41. Shen, WH. and others, 1998. Stability and distribution of orally administered epidermal growth factor in neonatal pigs. Life Sciences, 63 (10), 809–820; Rao, R.K. and others, 1998. Bovine milk inhibits proteolytic degradation of epidermal growth factor in human gastric and duodenal lumen. Peptides, 19 (3), 495–504; McCuskey, R.S. and others, 1997. Effect of milk-borne epidermal growth factor on the hepatic microcirculation and Kupfer cell function in suckling rats. Biology of the Neonate, 7 (3), 202–206; Oguchi, S. and others, 1997. Growth factors in breast milk and their effect on gastrointestinal development. Chang Hua Min Kuo Hsiao Ehr Ко I Hsuek Tsa Chih, 38 (5), 332–337.

42. Salomon, D.S. and others, 1999. Cripto: a novel epidermal growth factor (EGF)-related peptide in mammary gland development and neoplasia. Bioessays, 21 (1), 61–70; Chou, YC. and others, 1999. Induction of mammary carcinomas by N-meth-yl-N-nitrosurea in ovariectomized rats treated with epidermal growth factor. Carcinogenesis, 20 (4), 677–684; Kurtz, A. and

others, 1998. Local control of mammary gland differentiation: mammary-derived growth inhibitor and pleiotrophin. Biochemical Society Symposium, 63, 51–69; Taylor, M.R. and others, 1997. Lactadherin (formerly BA46); a membrane-associat-ed gycoprotein expressed in human milk and breast carcinomas, promotes Arg-Gly-Asp (RGD)-dependent cell adhesion. DNA and Cell Biology, 16 (7), 861–869.

43. Zhau, H.J. and others, 1996. Androgen-depressed phenotype in human prostate cancer. Proc. Natl. Acad. Sei. U.S.A., 93 (26), 15 152-15 157.

44. Thornburg, W. and others, 1984. Gastrointestinal absorption of epidermal growth factor in suckling rats. American Journal of Physiology, 246, G80—G85.

45. www.prostatepointers.org/cmyers/pf0696.html

46. Gaull, G.E. and others, 1985. Significance of growth modulators in human milk. Pediatrics, 75 (2), 142–145.

47. Delgrange, E. and others, 1997. Sex related differences in the growth of prolacrinomas: a clinical and proliferation marker study. Journal of Clinical Endocrinology and Metabolism. 82 (7), 2102–2107.

48. Vonderhaar, B.K., 1998, Prolactin: The forgotten hormone of human breast cancer. Pharmacology and Therapeutics, 79 (2), 169–178; Das, R. and others; 1996. Involvement of SHC, GRB2, SOS and RAS in prolactin signal transduction in mammary epithelial cells. Oncogene, 13 (6), 1139–1145; Mershon, J, and others, 1995. Prolactin is a local growth factor in rat mammary tumors. Endocrinology, 136 (8), 3619–3623; Ginsberg, E. and others, 1995. Prolactin secretion by human breast cancer cells. Cancer Res, 55 (12), 2591–2595; Fuh, G. and others, 1995. Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J Biol Chem, 270 (22), 13 133-13 137.

49. Leav, I. and others, 1999. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. American Journal of Pathology, 154 (3), 863–870; Horti, J. and others, 1998. A phase 2 study of bromocriptine in patients with androgen-independent prostate cancer. Oncology Reports, 5 (4), 893–896; Franklin, R.B. and others, 1997. Prolactin regulation of mitochondrial aspartate aminotransferase and proteinkinase С Molecular and Cellular Endocrinology, 127 (1), 19–25; Janssen, T. and others, 1996. In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate. Cancer, 77 (1), 144–149; Janssen, T. and others, 1995. Organ culture of human tissue as study model of hormonal and pharmacological regulation of benign prostatic hyperplasia and of prostatic cancer, (frans) Acta Urol Belg, 63 (1), 7-14; Oliver, R.T. and others, 1995. New directions with hormone therapy in prostate cancer: possible benefit from blocking prolactin and use of hormone treatment intermittently in combination with immunotherapy. Eur J Cancer, 31A (6), 859–860; Rana, A. and others, 1995. A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate. Eur J Cancer, 31A (6), 871–875.

50. Hinuma, S. and others, 1998. A prolactin-releasing peptide in the brain. Nature, 393 (6682), 272–276.

51. Smith, S.S. and others, 1986. Presence of luteinising hormone-releasing hormone (LHRH) in milk. Endocrinol Exp., 2 °C2-3), 147–153; Koldovsky, O., 1989. Search for the role of milk borne biologically active peptides for the suckling. J.Nu-tr., 119 (II), 1543–1551; Nair, R.M. and others, 1987. Studies on LHRH and physiological fluid amino acids in human colos-treum and milk. Endocrinolologia Experimentalise 21 (1), 23–30.

52. White, M.E. and others, 1986. Milk progesterone concentrations following simultaneous administration of buserelin and cloprostenol in cattle with normal corporal lutea. Canadian Journal of Veterinary Research, 50 (2), 285–286; Dinsmore, R.P. and others, 1989. Effect of gonadotropin-releasing hormone on clinical response and fertility in cows with cystyic ovaries, as related to milk progesterone concentration and days after partarition. Journal of the American Veterinary Medical Association, 195 (3), 327–330.

53. Berseth, C.I. and others, 1990. Postpartum changes in pattern of gastrointestinal regulatory peptides in human milk. Am J Clin Nutr, 51 (6), 985–990.

54. Berseth, C.I. and others, 1990. Postpartum changes in pattern of gastrointestinal regulatory peptides inhuman milk. Am J Clin Nutr, 51 (6), 985–990.

55. Flood, J.F. and others, 199L Increased food intake by neuropeptide Y is due to an increased motivation to eat. Peptides, 12 (6), 1329–1332.

56. Amarant, T. and others, 1982. Luteinising hormone-releasing hormone and thyrotropin-releasing hormone in human and bovine milk. European Journal of Biochemistry, 127 (3), 647–650; Baram, T and others, 1977. Gonadotropin-releasing hormone in milk. Science, 198 (4314), 300–302.

57. Koike, K. and others, 1997. The pituitary folliculo-stellate cell line TtT/GF augments basal and TRH-inducedprolactin secretion by GH3 cells. Life Sei, 61 (25), 2491–2497; Tyson, J.E. and others, 1975. The influence of prolactine secretion on human lactation./ Clin Endocrinol Met ah, 40 (5), 764–773.

58. Grochowska, R. and others, 1999. Stimulated growth hormone (GH) release in Friesian cattle with respect to GH genotypes. Reproduction Nutrition Development, 39 (2), 171–180; Bourne, R.A. and others, 1977. Serum growth hormone concentrations after growth hormone or thyroid-releasing hormone in cows. Journal of Dairy Science, 60 (10), 1629–1635.

59. Chomczinsky, E and others, 1993. Stimulatory effect of thyroid hormone on growth hormone gene expression in a human pituitary cell line. / Clin Endocrinol Metah, 77 (1), 281–285; Reynolds, A.M., 1991. The effects of chronic exposure to supra physiological concentrations of 3,5,3-triiodo-L-thyronine (T3) on cultured GC cell s. Journal of Cellular. Physiology, 149 (3), 544–547.

60. Tenore, A. and others, 1980. Thyroidal response to peroral TSH in suckling and weaned rats. American Journal of Physiology, 238 (5), E428-430.

61. Slebodzinski, A.B. and others, 1998. Triiodothyronine (T3), insulin and characteristics of 5’-monodiodinase (5’-MD) in mare’s milk from partarition to 21 days post-partum. Reproduction Nutrition Development, 38 (3), 235–244.

62. Fujimoto, N. and others, 1997. Upregulation of the estrogen receptor by triiodothyronine in rat pituitary cell lines. Journal of Steroid Biochemistry and Molecular Biology, 61 (1–2), 79–85.

63. Koldovsky, О., 1989. Search for the role of milk borne biologically active peptides for the suckling. J Nutr, 119 (11), 1543–1551; Buts, J.P., 1998. Bioactive factors in milk, (in French.) Arch Pediatr, 5 (3), 298–306.

64. Faulkner, A., 1998. Insulin-like growth factor concentrations in milk and plasma after growth hormone treatment. Biochemical Society Transactions, 26 (4), S386; Baldini, E. and others, 1994. In vivo cytokinetic effects of recombinant human growth hormone (rhGH) in patients with advanced breast carcinoma. Journal of Biological Regulators and Homeostatic Agents, 8 (4), 113–116; Scheven, B.A. and others, 1991. Effects of recombinant human insulin-like growth factor-1 and -2 (IGF) and growth hormone (GH) on the growth of normal adult human osteoblast-like cells and human osteogenic sarcoma cells. Growth Regulation, 1 (4), 160–167; Hodate, K. and others, 1990, Plasma growth hormone, insuline-like growth factor-1, and milk production response to exogenous human growth hormone-releasing factor analogs in dairy cows. Endocrinolo-gia Japonica, 37 (2), 261–273.

65. Koldovsky, O., 1989. Search for the role of milk borne biologically active peptides for the suckling. J Nutr, 119 (11), 1543–1551; Buts, J.P., 1998. Bioactive factors in milk, (in French.) Arch Pediatr, 5 (3), 298–306.

66. Westrom, B.R. and others, 1987. Levels of immunoreactive insulin, neurotensin, and bombesin in porcine colostreum and milk. / Pediatr Gastroenterol Nutr, 6 (3), 460–465; Ehman, R. and others, 1985. Bombesin, neurotensin and pro-gamma-mel-anotropin in immunoreactants in human milk. Regulatory Peptides, 10 (2–3), 99-105.

67. Shutt, D.A. and others, 1985. Comparison of total and free cortisol in bovine serum and milk colostreum. J Dairy Set, 68 (7), 1832–1834.

68. Vaarala, O. and others, 1998. Cow milk feeding induces antibodies to insulin in children – a link: between cow milk and insulin-dependent diabetes mellitus? Scandinavian Journal of Immunology 47 (2), 131–135; Slebodzinsky, A.B. and others,

1998. Triiodothyronine (T3), insulin and characteristics of 5’-monodiodinase (5’-MD) in mare’s milk from partarition to 21

days post-partum. Reprod Nutr Dev, 38 (3), 235–244; We-strom, B.R. and others, 1987. Levels of immunoreactive insulin, neurotensin, and bombesin in porcine colostreum and milk. J Pediatr Gastroenterol Nutr, 6 (3), 460–465.

69. Ferrando, T. and others, 1990. Beta-endorphin-like and alpha-MSH-like immunoreactivities in human milk. Life Sei, 47 (7), 633–635.

70. http://www.13.waisays.com/cancer2.htm; Newcomb, P.A. and Egan, K.M., 2006. Dairy food and ovarian cancer risk. The Lancet, March 2006, 797–799; Stang, A. and others, 2006. Adolescent milk fat and galactose consumption and testicular germ cell cancer. Cancer Epidemiology and Biomarkers Prevention, 15,2189–2195.

71. Maruuchi, T. and others, 1998. Effects of gonadotropin-releasing hormone agonist on rat ovarian adenocarcinoma cell lines in vitro and in vivo .Japanese Journal of Cancer Research, 89 (9), 977–983; Kuroda, H. and others, 1998. Human chorionic gonadotrophin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: possible role of up-regulation of IGF-1 by hCG. Int J Cancer, 76 (4), 571–578; Kurbacher, C.M. and others, 1995. Influence of luteinising hormone on cell growth and С A 125 secretion of primary epithelial ovarian carcinomas in vitro. Tumour Biology, 16 (6), 374–384; Manetta, A. and others, 1995. Inhibition of growth of human ovarian cancer in nude mice by luteinising hormone-releasing hormone antagonist Cetrorelix (SB-75). Fertility and Sterility, 63 (2), 282–287.

72. Reiter, E. and others, 1999. Effects of pituitary hormones on the prostate. Prostate, 38 (2), 159–165; Lamharzi, N. and others, 1998. Luteinising hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-2 in tumors. Regulatory Peptides, 77 (113), 185–192; Jungwirth, A. and others, 1997. Luteinising hormone-releasing hormone (LH-RH) antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-2 inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate, 32 (3), 164–172; Maeza-wa, H. and others, 1997. Potentiating effect of buserelin ace-t?te, an LHRH agonist on the proliferation of ventral prostatic epithelial cells in testosterone-treated castrated rats. Int J Urol,

4 (4), 411–416; Using, АЖ and others, 1993. Serological precursors of cancer serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev, 2 (1), 27–32; Garde, S. and others, 1993. Effect of prostatic inhibiting peptide on prostate cancer cell growth in vitro and in vivo. Prostate, 7 (2), 183–194.

73. Bosland, M.C., 1996. Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models. Progress in Clinical and Biological Research, 394, 309–352.

74. Chapman, S. and others, 1992. Changes in adult cigarette consumption per head in 128 countries, 1986–1990. Tobacco Control, 1,281–284.

75. http://www.who.int

76. Chapman, S. and others, 1992. Changes in adult cigarette consumption per head in 128 countries, 1986–1990. Tobacco Control,, 1.281–284.

77. http://www.who.int

78. http://www.13.waisays.com/cancer2.htm

79. Underwood, L.E., D’Ercole, J.A. and Van Wyk, J.J., 1980. So-matomedin-C and the assessment of growth. Ped ClinN Amer,

27, 4, 771–782, and Perdue, J.E 1984. Chemistry, structure and function of insulin-like growth factors and their receptors: a review. Can J Вiochem Cell Bio, 62, 1237–1245.

80. http://vw.com/healthnews/milk.html

81. Pollack, Michael, 2003. Cancer, aging and IGF physiology. Meeting of the Royal Society of Medicine in London in October 2003, entitled „Biology of IGF-I: its interaction with insulin in health and malignant statescc.

82. Lonning, Per Eystein, 2003. IGF-I and breast cancer. Meeting of the Royal Society of Medicine in London in October 2003, entitled „Biology of IGF-I: its interaction with insulin in health and malignant statescc.

83. Yee, Doug, 2003. Targeting the IGF system for anti-tumour therapy. Meeting of the Royal Society of Medicine in London in October 2003, entitled „Biology of IGF-I: its interaction with insulin in health and malignant statescc.

84. Pollack, Michael, 2003. Cancer, aging and IGF physiology. Meeting of the Royal Society of Medicine in London in October 2003, entitled ‘Biology of IGF-I; its interaction with insulin in health and malignant states’.

85. Holly, Jeff, 1998. Insulin-like growth factor-1 and new opportunities for cancer prevention. Lancet, 351, 9113, 9 May, 1373–1375.

86. Chan, J.M., Stampfer, M.J., Giovannucci, E. and others, 1998. Plasma insulin-like growth factor-I and prostate cancer risk; a prospective study. Science, 279, 563–566; Harman, S.M., Metter, E.J., Blackmail, M.R., Landis, EK. and Carter, H.B., 2000. Serum levels of insulin-type growth factor 1 (IGF-I), IGF II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab, 85, 4258–4265; Stattin, E and nine others, 2000. Flasma insulin-like growth factor-I insulin-like growth-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst, 92, 1910–1917; Chokkalingam, A.F, and 12 others, 2001. Insulinlike growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev, 10, 421–427; Chan, J.M., Stampfer, M.J., Ma, J. and others, 2002. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst, 94, 1099–1106; Mantzoros, C.S., Tzonou, A., Signorello, L.B. and others, 1997. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. British Journal of Cancer, 76, 1115–1118; Wolk, A., Mantzoros, C.S., Anders-son, S.O. and others, 1998. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst, 90, 911–915; Holly, J.M.E, Gunnell, D.J. and Davey Smith., G, 1999. Growth hormone, IGF-1 and cancer. Less intervention. Less intervention to avoid cancer? More intervention to prevent cancer. J Endocrinol, 162, 321–330.

87. Yu, H. and others, 1999. Flasma levels of IGF-I and lung cancer risk, Journal of the National Cancer Institute, 91, 151–156.

88. Ma, J. and others, 2001. Milk intake, circulating levels of IGF-1 and risk of colorectal cancer in men. Journal of the National Cancer Institute, 93 (17), 1330–1336.

89. LeRoith, D. and others, 1995. The role of the IGF-I receptor in cancer. Annals of the New York Academy of Sciences, 766, 402–408; Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

90. Campbell, T. Colin, Campbell, Thomas M. II, Robbins, John and Lyman Howard, 2006. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Health. Ben-bella Books.

91. Bradford Hill, A., 1965. The environment and disease; association or causation? Proceedings of the Royal Society of Medicine,

58, 295–300.

92. Holly, J.M.P., Gunnell, D.J. and Davey Smith, G., 1999. Growth hormone, IGF-I and cancer. Less intervention. Less intervention to avoid cancer? More intervention to prevent cancer. J Endocrinol, 162, 321–330.

93. Bobbins, John, 1987. A Diet for a New America, Stillpoint Publishing.

94. www.dhn.csiro-au/crctissue.html

95. Xian, C., 1995. Degradation of IGF-I in the Adult Rat Gastrointestinal Tract is limited by a Specific Antiserum of the Dietary Protein Casein .Journal of Endocrinology, 146, 2, 1 August, 215; Thornburg, Ж and others, 1984. Gastrointestinal absorption of epidermal growth factor in suckling rats. American Journal of Physiology, 246, G80-G85.

96. The European Commission. Health and Consumer Protection. Scientific Committee on Veterinary Measures relating to Public Health – Outcome of discussions.

http://europa.eu.int/comm/dg24/health/ sc/scv/ outl9_en.html

97. Allen, N.K, and others, 2000, Hormones and Diet; Low Insulin-like Growth Factor-1 but Normal Bioavailable Androgens in Vegan Men. Brit J Cane, 83 (1), 95–97.

98. Steinman, G., 2006. Can the chance of having twins be modified by diet? The Lancet, 367 (9521), 1461–1462.

99. Norat and others, 2007. Diet, serum IGF-1 and IGF-BP3 in European women. European Journal of Clinical Nutrition, 61, 91–98.

100. The European Commission. Health and Consumer Protection. Scientific Committee on Veterinary Measures relating to Public Health – Outcome of discussions. http://europa.eu.int/comm/dg24/health/sc/scv/outl9_ en.html

101. Heaney, R.P. and others, 1999. Dietary changes favourably affect bone remodelling in older adults, Journal of the American Dietetic Association, 99 (10), 1228–1233.

102. Gunnell, D.L. and 10 others, 2003. Are diet – prostate-can-cer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. British Journal of Cancer, 88, 1682–1686.

103. World Cancer Research Fund, 1997. Food, nutrition and the prevention of cancer: a global perspective. Washington, DC: American Institute of Cancer Research.

104. Allen, N.E., Appleby, P.N., Davey, G. K. and Key, T.J., 2000. Hormones and diet: low insulin-like growth factor-I but normal bioavailable androgens in vegan men. Br J Cancer. 83, 95–97.

105. Yaker, S. and others, 2005. The role of the growth hormone/ IGF axis in tumour growth and progression: lessons from animal models. Cytokine and Growth Factor Reviews, 16 (4–5), 407–420; Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

106. Mannisto, S. and others, 1999. Diet and the risk of breast cancer in a case control study: does the threat of disease have an influence on recall bias? Journal of Clinical Epidemiology, 52 (5), 429–439; Outwater, J.L. and others, 1997. Dairy products and breast cancer: the IGF-1, estrogen and bGH hypothesis. Medical Hypotheses, 48 (6), 453–461; Gaard, M. and others, 1995. Dietary fat and the risk of breast cancer: a prospective study of 25 892 Norwegian women. Int J Cancer, 63 (1), 13–17; Decarli, A. and others, 1986, Environmental factors and cancer mortality in Italy: correlational exercise. Oncology, 43 (2), 116–126; Rose, D.P. and others, 1986. International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. Cancer, 58 (11), 2363–2371; Shimada, A. and others, Ecological approach to the eating habits and the cancer mortality of Brazilian people, (in het Japans) Can No Rinsho, 32 (6), 631–640; La Vecchia, C. and others, 1986, Age at first birth, dietary practises and breast cancer mortality in various Italian regions. Oncology, 43 (1), 1–6; Talamini, R. and others, 1984. Social factors, diet and breast cancer in a northern Italian population. Br J Cancer. 49 (6), 723–729.

107. Rose, D. P. and others, 1986. International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. Cancer, 58 (11), 2363–2371.

108. Schuurman, A.G. and others, 1999, Animal products, calcium and protein and prostate cancer risk in The Netherlands Cohort Study, Br J Cancer, 80 (7), 1107–1113; Giovannucci, E., 1999. Nutritional factors in human cancers. Advances in Experimental Medicine and Biology, 472, 29–42; Giovanucci, E., 1998. Dietary influences of 1,25 (OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes and Control, 9 (6), 567–582; Willet, WC., 1997. Nutrition and Cancer. Sa-lud Publica de Mexico, 39 (4), 298–309; De Stefani, E. and others, 1995, Tobacco, alcohol, diet and risk of prostate cancer. Tumori, 81 (5), 315–320; Le Marchand, L. and others, 1994. Animal fat consumption and prostate cancer: a prospective study in Hawaii. Epidemiology, 5 (3), 276–282; Talamini, R. and others, 1992. Diet and prostate cancer: a case control study in northern Italy. Nutrition and Cancer, 18 (3), 277–286; La Vecchia, C. and others, 1991. Dairy products and the risk of prostatic cancer. Oncology, 48 (5), 406–410; Mett-lin, C. and others, 1989. Beta-carotene and animal fats and their relationship to prostate cancer risk. A case control study. Cancer, 64 (3), 605–612; Snowdon, D.A., 1988. Animal product consumption and mortality because of all causes combined, coronary heart disease, stroke, diabetes, and cancer in Seventh-day Adventists. Am J Clin Nutr, 48 (3 Suppl), 739–748; Talamini, R. and others, 1986. Nutrition, social factors, and prostate cancer in a northern Italian population. Br J Cancer, 53 (6), 817–821; Rose, D.P. and others, 1986. International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. Cancer, 58 (11), 2263–2271.

109. Newby, JA. and Howard, 2006. Environmental influences in cancer aetiology, 2006, 1-59.

110. Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

111. Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

112. Lawrence R., 1994. Breastfeeding – A Guide to the Medical Profession, Fourth edition. Mossby.

113. Holly, J.M.P., Gunnell, D.J. and Davey Smith, G., 1999. Growth hormone, IGF-I and cancer. Less intervention to avoid cancer? More intervention to prevent cancer? J Endocrinol, 162, 321–330.

114. Giudice, L.A., 1992. Insulin-like growth factors and ovarian follicular development. Endocrine Reviews, 13, 641–669.

115. Westlev, B.R. and May, F.E.B., 1994. Role of insulin-like growth factors in steroid modulated proliferation. Journal of Steroid Bioehemistry and Molecular Biology, 51, 1–9; Marcelli, M., Haidacher, S.J., Plymate, S.R. and Birnbaum, R.S., 1995. Altered growth and insulin-like growth factor-binding protein-3 production in PC-3 prostate carcinoma cells stably transfected with a constitutively active androgen receptor complementary deoxyribonucleic acid. Endocrinology, 136, 1040–1048.

116. Holly, J.M.P., Gunnell, D.J. and Davey Smith, G., 1999. Growth hormone, IGF-I and cancer. Less intervention to avoid cancer? More intervention to prevent cancer? J Endocrinol, 162, 321–330.

117. Bernstein, I. and Ross, R.K., 1993. Endogenous hormones and breast cancer risk. Epidemiol Res, 15, 48–65; Pike, M.C. and others, 1993. Estrogens, progestogens, normal breast proliferation and breast cancer risk. Epidemiol Reviews, 15, 17–35.

118. Bocchinfuso, WF. and others, 2000. Induction of mammary gland development in estrogen receptor-alpha knoclout mice. Endocrinology; 141; 2983–2994; Attwood, C.S. and others,

2000. Progesterone induces side-branching of the ductal epithelium in the mammary glands of prepubertalmice. J Endocrinology, 167, 39–52.

119. Campbell, T. Colin, Campbell, Thomas M. II, Robbins, John and Lyman Howard, 2006. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Healths. Benbella Books.

120. www.breakthrough.org.uk

121. Campbell, T. Colin, Campbell, Thomas M. II, Robbins, John and Lyman Howard, 2006. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Health. Benbella Books.

122. Cramer, D.W and others, 1989. Galactose consumption and metabolism in relation to the risk of ovarian cancer Lancet, 2, 66–71.

123. Fairfield and others, 2004. A prospective study of dietary lactose and ovarian cancer. Int J of Cancer, 110 (2), 271–277.

124. Larsson, S.C. and others, 2004. Milk and lactose intakes and ovarian cancer risk. In the Swedish Mammography Cohort. Amer J Clinical Nutrition, 80 (5), 1353–1357.

125. Larsson, S.C. and others, 2005. Milk, milk products and lactose intake and ovarian cancer risk: a meta analysis of epidemiological studies. Int J of Cancer.

126. Ganmaa, D. and Sato, A., 2005. Possible role of female sex hormones in milk from pregnant cows in the development of breast, ovarian and corpus uteri cancers. Medical Hypotheses, 65 (6), 1028–1037.

127. Hartman, S. and others, 1998. Natural occurrence of steroid hormones in food. Food Chemistry, 62, 7-20; Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

128. Plant, Jane and Tidey, Gill, 2005. Eating for Better Health. Virgin Books.

129. Bahna, S,L., 1987. Milk allergy in infancy. Ann Allergy. 59, 131.

130. Dunea, G., 1982. Beyond the Etheric. BMJ, 285, 428–429.

131. Kretchmer, N., 1981. The Significance of lactose intolerance. In: Paige, D.M. and Bayless, T.M., Editors., Lactose Digestion: Clinical and nutritional implications. Johns Hopkins University Press.

132. http://www.fda.gov/fdac/features/2OOV4 01_food.html

133. http://www.ifst.org/hottopl9.htm

134. Taylor, S.L., 1992. Chemistry and detection of food allergens. Food Technology, 46 (5), 146–152.

135. Saarinen, K.N. and others, 2005. Clinical course and prognosis of cow’s milk allergy are dependent on milk-specific IgE statu s. Journal of Allergy and Clinical immunology, 136 (4), 869–875.

136. http://www.ifst.org/hottopl9.htm

137. Martin, Peter, 2002. Milk: Nectar or poison? Sunday Times Magazine, July 21. 2002.

138. Thorsdottir, I. and Ramel, A., 2003. Dietary intake of 10– to 16-year-old children and adolescents in Central and Northern Europe and association with the incidence of type-1 diabetes. Annals of Nutrition and Metabolism, 47 (6), 267–275.

139. Campbell, T. Colin, Campbell, Thomas M. II, Robbins, John and Lyman Howard, 2006. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Health. Benbella Books.

140. ТВ bacteria found in treated milk. Sunday Times, 20 February, 2000.

141. Bull, T.J. and others, 2003. Detection and verification of My-cobactenum avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without

Crohn’s disease, Journal of Clinical Microbiology. 41 (7), 2915–2923.

142. Millar, D. and others, 1996. IS900 PCR to detect Mycobacterium paratuberculosis in retail supplies of whole pasteurized cows’ milk in England and Wales. Applied and Environmental Microbiology, 62 (9), 3446–3452.

143. Pickup, R.W and others, 2005. MAP in the catchment area and water of the River Taff in South Wales, UK and its potential relationship to clustering of Crohn’s disease cases in the city of Cardiff. Applied and Environmental Microbiology, 71 (4), 2130–2139.

144. FSA/SE, 2001. Task force on E.coli 0157.

www.f ood. gov.uk/ mnltimedia/pdfs/ecolitaskfinreport.pdf

145. Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

146. Plant, Jane and Tidey, Gill, 2003. Understanding, Preventing and Overcoming Osteoporosis. London: Virgin Books.

147. Robbins, John, 1987. A Diet for a New America. Stillpoint Publishing.

148. Hegsted D.M., 1986. Calcium and osteoporosis. J Nutr, 116, 2316–2319.

149. Campbell, T. Colin, Campbell, Thomas M. II, Robbins, John and Lyman Howard, 2006. The China Study: The Most Comprehensive Study of Nutrition Ever Conducted and the Startling Implications for Diet, Weight Loss and Long-term Health. Benbella Books.

150. Ademamowo, C.A. and others, 2005. High-school dietarv dairy intake and teenage acne. Journal of the American Academy of Dermatology, 52 (2), 207–214.

151. Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

152. Toohey, M.L., and others, 1998. Cardiovascular disease risk factors are lower in African-American vegans compared to lacto-ovo-vegetarians. Journal of the American College of Nutrition, 17 (5), 425–434.

153. Park, M. and others, 2005. Consumption of milk and calcium in mid-life and the future risk of Parkinson disease. Neurology, 64, 1047–1051.